Ipsen SA (WBO:IPN)
€ 109.6 -2.5 (-2.23%) Market Cap: 9.03 Bil Enterprise Value: 8.81 Bil PE Ratio: 13.46 PB Ratio: 2.37 GF Score: 95/100

Ipsen SA at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 09:30PM GMT
Release Date Price: €7.72
Richard Vosser
JP Morgan Chase & Co, Research Division - Senior Analyst

Good afternoon. Welcome to the Ipsen presentation at the JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan, and it's my great pleasure to introduce the CEO and CFO, Aymeric Le Chatelier, from Ipsen.

Before I hand over to Aymeric, the breakout session following this presentation is in the Georgian Room, which is just around the corner. Aymeric, welcome to the conference.

Aymeric Le Chatelier
Ipsen S.A. - Executive VP, Interim CEO & CFO

Okay, thank you. Thank you very much, Richard. I'm very pleased to be with you this afternoon and to provide you with an update on Ipsen.

So clearly -- before the safe harbor, so clearly, at Ipsen, we continue to deliver on our vision of being a leading global biopharma focused on innovation and specialty care. And as you see, we are growing our 2 businesses, I mean, our specialty care business accounting for almost 90% of our sales, focusing on 3 therapeutic area, being oncology, more than 70

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot